KLRA
Kailera Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-29/100
Last price
10.83
▼ 0.01 (0.09%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
10.84
Day high
11.24
Day low
10.32
Volume
1.45M
Market cap
$1.40B
P/E (TTM)
—
52W range
9.85 – 28.23
Trailing performance
Returnvs SPY
1W
-1.46%
-3.4%
1M
-33.27%
-34.4%
3M
-50.23%
-54.7%
6M
—
-18.2%
YTD
-58.35%
-72.6%
1Y
—
-16.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on KLRA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
11.55M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 9, 26 | RENAUD RONALD C JR Chief Executive Officer |
CONVERSION | 38.09K | $199.99K | Direct |
| Apr 20, 26 | KOPPEL ADAM M Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.56M | $40.63M | Indirect |
| Apr 20, 26 | KOPPEL ADAM M Director and Beneficial Owner of more than 10% of a Class of Security |
— | 21.02M | — | Indirect |
| Apr 20, 26 | BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.56M | $38.45M | Indirect |
| Apr 20, 26 | BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC Beneficial Owner of more than 10% of a Class of Security |
— | 21.02M | — | Indirect |
| Apr 20, 26 | RTW INVESTMENTS, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 500.00K | $12.30M | Indirect |
| Apr 20, 26 | RTW INVESTMENTS, L.P. Beneficial Owner of more than 10% of a Class of Security |
— | 10.28M | — | Indirect |
| Apr 20, 26 | KAPLAN ANDREW T Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 8.40M | $218.36M | Indirect |
| Apr 20, 26 | KAPLAN ANDREW T Director and Beneficial Owner of more than 10% of a Class of Security |
— | 17.86M | — | Indirect |
| Apr 20, 26 | BAIN CAPITAL INVESTORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
BUY | 8.40M | $218.36M | Indirect |
| Apr 20, 26 | BAIN CAPITAL INVESTORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
— | 17.86M | — | Indirect |
| Apr 20, 26 | JIANGSU HENGRUI PHARMACEUTICALS CO. LTD. Beneficial Owner of more than 10% of a Class of Security |
— | 11.51M | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAIN CAPITAL INVESTORS, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
JIANGSU HENGRUI PHARMACEUTICALS CO. LTD. |
Beneficial Owner of more than 10% of a Class of Security | 2.03M | Conversion of Exercise of derivative security |
KAPLAN ANDREW T |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
KOPPEL ADAM M |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
RENAUD RONALD C JR |
Chief Executive Officer | 38.09K | Conversion of Exercise of derivative security |
RTW INVESTMENTS, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
Fundamentals
Market cap$1.40B
Enterprise value$497.52M
Revenue (TTM)—
Gross profit—
EBITDA$-312.88M
Net income$-292.20M
EPS (TTM)$-4.51
Free cash flow—
Total cash$916.74M
Total debt$10.22M
Book value / share$8.63
Shares outstanding129.64M
Float58.48M
Short % of float4.60%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.52
PEG ratio—
Price / sales—
Price / book1.26
EV / revenue—
EV / EBITDA-1.59
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity0.91
Current ratio11.11
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | YoY |
|---|---|---|
| Total revenue | $0 | |
| Operating revenue | $0 | |
| Research & development | $109.11M | |
| Selling, general & admin | $49.23M | |
| Total operating expense | $158.34M | |
| Operating income | -$158.34M | |
| Net interest income | $11.05M | |
| Pre-tax income | -$148.96M | |
| Net income | -$148.96M | |
| Net income to common | -$148.96M | |
| Basic EPS | -1.26 | |
| Diluted EPS | -1.26 | |
| EBIT | -$158.34M | |
| EBITDA | -$158.03M | |
| Basic shares | 117.95M | |
| Diluted shares | 117.95M |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Cash & equivalents | $160.27M | $175.18M | -8.5% |
| Cash & short-term investments | $546.06M | $175.18M | +211.7% |
| Total current assets | $557.54M | $177.61M | +213.9% |
| Property, plant & equipment | $12.42M | $680.00K | +1,726.2% |
| Total assets | $692.29M | $178.44M | +288.0% |
| Total current liabilities | $46.41M | $6.91M | +571.5% |
| Total debt | $10.75M | $509.00K | +2,012.6% |
| Total liabilities | $1.05B | $397.22M | +164.0% |
| Retained earnings | -$368.67M | -$219.71M | -67.8% |
| Shareholder equity | -$356.46M | -$218.77M | -62.9% |
| Working capital | $511.13M | $170.70M | +199.4% |
| Net tangible assets | -$356.46M | -$218.77M | -62.9% |
| Shares issued | 117.95M | 117.95M | 0.0% |
| Line item | 2025 | YoY |
|---|---|---|
| Net income | -$148.96M | |
| Depreciation & amortisation | $310.00K | |
| Stock-based compensation | $10.94M | |
| Change in working capital | $16.78M | |
| Operating cash flow | -$120.21M | |
| Capital expenditure | -$2.09M | |
| Investing cash flow | -$492.60M | |
| Financing cash flow | $598.66M | |
| Free cash flow | -$122.30M | |
| End cash position | $161.03M |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $101.06M | $70.87M | $19.52M | $10.13M | +42.6% |
| Selling, general & admin | $20.31M | $13.79M | $11.13M | $10.33M | +47.3% |
| Total operating expense | $121.37M | $84.66M | $30.65M | $20.46M | +43.4% |
| Operating income | -$121.37M | -$84.66M | -$30.65M | -$20.46M | -43.4% |
| Net interest income | $9.99M | $5.72M | $2.13M | $1.68M | +74.8% |
| Pre-tax income | -$111.31M | -$78.86M | -$28.95M | -$17.98M | -41.1% |
| Net income | -$111.31M | -$78.86M | -$28.95M | -$17.98M | -41.1% |
| Net income to common | -$111.31M | -$78.86M | -$28.95M | -$17.98M | -41.1% |
| Basic EPS | -1.09 | -0.67 | -0.25 | -0.15 | -63.0% |
| Diluted EPS | -1.09 | -0.67 | -0.25 | -0.15 | -63.0% |
| EBIT | -$121.37M | -$84.66M | -$30.65M | -$20.46M | -43.4% |
| EBITDA | -$121.27M | -$84.56M | -$30.59M | -$20.39M | -43.4% |
| Basic shares | 102.23M | 117.95M | 117.95M | 117.95M | -13.3% |
| Diluted shares | 102.23M | 117.95M | 117.95M | 117.95M | -13.3% |
| Line item | 2026-06-30 | 2026-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $130.30M | $111.83M | +16.5% |
| Cash & short-term investments | $916.74M | $519.17M | +76.6% |
| Total current assets | $929.17M | $530.32M | +75.2% |
| Property, plant & equipment | $11.65M | $12.02M | -3.1% |
| Total assets | $1.21B | $624.76M | +93.9% |
| Total current liabilities | $83.65M | $54.84M | +52.5% |
| Total debt | $10.22M | $10.47M | -2.4% |
| Total liabilities | $92.95M | $1.06B | -91.2% |
| Retained earnings | -$558.84M | -$447.53M | -24.9% |
| Shareholder equity | $1.12B | -$432.09M | +358.9% |
| Working capital | $845.52M | $475.48M | +77.8% |
| Net tangible assets | $1.12B | -$432.09M | +358.9% |
| Shares issued | 129.62M | 117.95M | +9.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Net income | -$111.31M | -$78.86M | -$28.95M | -$17.98M | -41.1% |
| Depreciation & amortisation | $101.00K | $101.00K | $62.00K | $63.00K | 0.0% |
| Stock-based compensation | $8.34M | $3.94M | $1.63M | $1.52M | +111.8% |
| Change in working capital | $26.72M | $7.47M | $1.34M | -$984.00K | +257.9% |
| Operating cash flow | -$77.53M | -$68.31M | -$26.23M | -$18.20M | -13.5% |
| Investing cash flow | -$571.02M | $22.85M | -$74.17M | -$54.44M | -2,599.1% |
| Financing cash flow | $667.03M | -$2.98M | $100.00M | $0 | +22,483.4% |
| Free cash flow | -$77.53M | -$68.31M | -$26.23M | -$18.20M | -13.5% |
| End cash position | $131.06M | $112.59M | $102.13M | $102.54M | +16.4% |
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
10.00
-7.7% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
10
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
10.00
0 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.73 | -1.09 | -49.4% |
| Mar 2026 | -0.55 | -3.65 | -565.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.01 | 5 | $0 | — |
| Next quarter | -1.16 | 5 | $0 | — |
| Current year | -4.10 | 5 | $0 | — |
| Next year | -4.30 | 5 | $0 | 0.0% |
Analyst targets & ownership
Mean target$42.40
High target$57.00
Low target$30.00
Implied upside291.51%
Analyst count5
ConsensusSTRONG BUY
Strong buy / Buy1 / 5
Hold0
Sell / Strong sell0 / 0
Held by insiders8.91%
Held by institutions90.35%
Institutions holding148
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
11.29
-4.12% from price
SMA 20
12.35
-12.33% from price
SMA 50
15.42
-29.76% from price
SMA 100
17.91
-39.55% from price
SMA 200
—
—
EMA 12
11.57
-6.36% from price
EMA 26
13.01
-16.73% from price
EMA 50
14.86
-27.11% from price
RSI (14)
32.3
Neutral
MACD (12,26,9)
-1.44
Hist -0.00
ATR (14)
0.93
8.58% of price
Realised vol 30D
80.4%
Annualised
Bollinger upper
15.03
20, 2σ
Bollinger lower
9.67
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.91
Less volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
80.4%
Annualised
Market vol 1Y
12.0%
SPY, annualised
Max drawdown 1Y
-60.0%
Peak to trough
Max drawdown 5Y
-60.0%
Peak to trough
ATR 14
0.93
8.58% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
5.96M
Prior 6.07M
Change vs prior
-1.7%
Shorts covering
% of float
4.60%
Normal
% of shares out
4.60%
Against total outstanding
Days to cover
7.1
Crowded exit
Float
58.48M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 12, 26 | Leerink Partners | INITIATED | — | Outperform |
| May 12, 26 | Jefferies | INITIATED | — | Buy |
| May 12, 26 | Evercore ISI Group | INITIATED | — | Outperform |
| May 12, 26 | JP Morgan | INITIATED | — | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-12
Periodic Financial Reports
10-Q · 2026-05-26
Corporate Changes & Voting Matters
8-K · 2026-04-20
Offering Registrations
S-1MEF · 2026-04-16
Trading Registrations
8-A12B · 2026-04-14
Offering Registrations
S-1/A · 2026-04-13
Offering Registrations
S-1 · 2026-03-27
Offering Registrations
DRS/A · 2026-02-11
Headlines
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
GlobeNewswire · 6d ago
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy
Motley Fool · 6d ago
Kailera Therapeutics Completes Enrollment for Trial of Ribupatide to Treat Obesity
MT Newswires · 7d ago
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
GlobeNewswire · 7d ago
Kailera Therapeutics to Participate in September Investor Conferences
GlobeNewswire · 21d ago
Jim Cramer Calls Kailera Therapeutics (KLRA) “The Most Speculative Stock On Earth”
Insider Monkey · 22d ago
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
24/7 Wall St. · 50d ago
Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified?
Simply Wall St. · 51d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.